Valence8 US LP Acquires Shares of 19,939 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Valence8 US LP bought a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 19,939 shares of the biotechnology company’s stock, valued at approximately $207,000. Valence8 US LP owned approximately 0.09% of Enanta Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after purchasing an additional 134,292 shares in the last quarter. Farallon Capital Management LLC raised its position in shares of Enanta Pharmaceuticals by 3.5% in the first quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after buying an additional 70,000 shares in the last quarter. Cubist Systematic Strategies LLC boosted its stake in shares of Enanta Pharmaceuticals by 65.8% in the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 18,003 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at approximately $122,000. Finally, Virtu Financial LLC acquired a new stake in Enanta Pharmaceuticals during the first quarter worth approximately $191,000. Institutional investors own 94.99% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. JMP Securities reiterated a “market outperform” rating and set a $22.00 target price on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 9th. Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. JPMorgan Chase & Co. decreased their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a report on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Enanta Pharmaceuticals Stock Up 3.0 %

NASDAQ:ENTA opened at $9.35 on Friday. Enanta Pharmaceuticals, Inc. has a twelve month low of $8.51 and a twelve month high of $17.80. The stock’s 50-day simple moving average is $11.20 and its 200 day simple moving average is $12.45. The firm has a market capitalization of $198.12 million, a PE ratio of -1.72 and a beta of 0.56.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.